timothy sykes logo

Stock News

Soleno Stock Skyrockets Amid New FDA Approval

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Ellis Hobbs Fact-checked by Matt Monaco
Soleno Stock Skyrockets Amid New FDA Approval Thumbnail

Soleno Therapeutics Inc. is seeing a potential positive market impact with the stock trading up by 7.51 percent on Friday, likely driven by news about a significant acquisition or a successful clinical trial.

Major Developments and Market Reactions

  • The latest triumph for Soleno Therapeutics came as the U.S. Food and Drug Administration approved VYKAT XR, a treatment for hyperphagia in individuals with Prader-Willi Syndrome, set to be available from April 2025.

Candlestick Chart

Live Update At 17:03:16 EST: On Friday, March 28, 2025 Soleno Therapeutics Inc. stock [NASDAQ: SLNO] is trending up by 7.51%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

  • Soleno’s shares recently surged by an astounding 37% following this monumental approval, which coincides with increased confidence from investors and raised target prices from brokerage firms.

  • Analysts at Cantor Fitzgerald and Laidlaw raised their price targets for Soleno Therapeutics to $123 and $105, respectively, suggesting a bullish outlook on the company’s market standing.

  • This therapeutic breakthrough positions Soleno as a key player in tackling hyperphagia, a significant challenge for patients with Prader-Willi syndrome, with the absence of direct competition enhancing its market position.

Financial Landscape and Performance Analysis

In the world of trading, maintaining a balance between risk and reward is crucial for long-term success. Many new traders often dive into the market with the hope of making fast money, without fully understanding the potential risks involved. This can lead to significant losses if market conditions change unpredictably. As millionaire penny stock trader and teacher Tim Sykes says, “It’s better to go home at zero than to go home in the red.” Embracing this mindset encourages traders to prioritize capital preservation over reckless gambling. Long-term success is built on consistent, careful trading rather than chasing every opportunity regardless of the accompanying risk.

In March 2025, the closing share price of Soleno Therapeutics bobbed around $71.99, reflecting increased investor confidence and market traction owing to recent FDA approval for its drug VYKAT XR. This FDA nod has sent ripples across the financial markets, lifting SLNO stocks, although analysts note a mixed bag of financial indicators that investors should scrutinize before diving into this seemingly promising stock.

Dive into the finance pool of Soleno, and one finds peculiar aspects of cash flows and income statements tugging in different directions. The company posted around $87.93M in cash by the end of the last fiscal quarter, a reflection of strategic management amidst large cash burn demands and operating losses. Revenue wasn’t as forthcoming captured in metrics, painting an ambiguous picture of the immediate revenue influx from VYKAT XR as the drug globalizes its available market piece by piece, patient by patient.

More Breaking News

The Company’s profitability ratios hover in elusive air, with return measures highlighting current operational losses. A delicate balancing act looms, as stakeholders eye the news of increased price targets as a lifeline harbinger for robust valuation recalibrations. It’s a village syndrome for investors — rejoice at potential triumphs, reckon with financial loses immediate, ponder a cautiously optimistic horizon.

Market Reaction and Future Implications: Explosive Rise in SLNO Shares

The bubbling excitement around Soleno stems from the recent show-stopping FDA approval, and analysts picking it apart feel cheery about its genetic platform future. Concerns linger not over efficacy but market gain realism; investors have found themselves in zestful fervor over the coming retail months. Is an unchallenged product? VYKAT XR enters a swath of big league; it emerges as the solo hero enhancing those suffering hyperphagiac challenges within Prader-Willi. A global niche sans competition.

In April, industry observers expect a consequential shift, as stakeholders rinse and repeat approval traction strategies. Soleno seems on the brink of re-shuffling its standing – facing a trilogy of prospects: Sky-high opportunity via market expansion, pragmatic reality in productivity enhancements, and calculated anticipation for it grips we shall soon perceive through each patient treated, each market spill, their share price as imperative.

Over $1.48B in enterprise value pushes inquiries into tangible equity returns and potential for leveraging. Critiques remain delicate – attach such aspirational planning with similar precision consultancy governance, profitability potential examiners believe favors solvent maneuverability.

Conclusion

Soleno Therapeutics rides the advantageous wave of FDA victory, beckoning more expansive strategic plays channeled through reinforced market holdings and forward-thinking capital infusion essentials. Is it time to plunge-hook entry alongside evolving drug market ripple? As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” Opportunities exist, beckoning and daring looms, imbibed on future vows and collaborative gains, each grounded uniquely nurturing a slingshot pursuit — does the stock deliver, wherein the medicine vowed? Traders must verify successes, carry prowess, and obtain vulnerabilities — many driven past obstacles no longer observed – change vista.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”